DE69824853D1 - Zusammensetzungen und gegenstände zur verminderung der auswirkung von entzündungen - Google Patents

Zusammensetzungen und gegenstände zur verminderung der auswirkung von entzündungen

Info

Publication number
DE69824853D1
DE69824853D1 DE69824853T DE69824853T DE69824853D1 DE 69824853 D1 DE69824853 D1 DE 69824853D1 DE 69824853 T DE69824853 T DE 69824853T DE 69824853 T DE69824853 T DE 69824853T DE 69824853 D1 DE69824853 D1 DE 69824853D1
Authority
DE
Germany
Prior art keywords
tissue
injured tissue
photosensitizing agent
injured
andb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69824853T
Other languages
English (en)
Other versions
DE69824853T2 (de
Inventor
C Stewart
Mario Fsadni
M Richter
G Levy
A Hariton
Gustav Huber
Modestus Obochi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Novelion Therapeutics Inc
Novartis AG
Original Assignee
University of British Columbia
QLT Inc
Quadra Logic Technologies Inc
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/942,883 external-priority patent/US6274614B1/en
Application filed by University of British Columbia, QLT Inc, Quadra Logic Technologies Inc, Novartis AG filed Critical University of British Columbia
Publication of DE69824853D1 publication Critical patent/DE69824853D1/de
Application granted granted Critical
Publication of DE69824853T2 publication Critical patent/DE69824853T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69824853T 1997-02-11 1998-01-14 Zusammensetzung und Gegenstände zur Verminderung der Auswirkung von Entzündungen Expired - Lifetime DE69824853T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79796397A 1997-02-11 1997-02-11
US797963 1997-02-11
US942883 1997-10-02
US08/942,883 US6274614B1 (en) 1997-02-11 1997-10-02 Methods, compositions and articles for reducing or preventing the effects of inflammation
PCT/IB1998/000181 WO1998034644A1 (en) 1997-02-11 1998-01-14 Compositions and articles for reducing the effects of inflammation

Publications (2)

Publication Number Publication Date
DE69824853D1 true DE69824853D1 (de) 2004-08-05
DE69824853T2 DE69824853T2 (de) 2006-01-12

Family

ID=27121943

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69824853T Expired - Lifetime DE69824853T2 (de) 1997-02-11 1998-01-14 Zusammensetzung und Gegenstände zur Verminderung der Auswirkung von Entzündungen

Country Status (14)

Country Link
US (1) US6677366B2 (de)
EP (1) EP0996465B1 (de)
JP (2) JP4012575B2 (de)
CN (1) CN1187089C (de)
AT (1) ATE270114T1 (de)
AU (1) AU734366B2 (de)
CA (1) CA2279427C (de)
CZ (1) CZ295734B6 (de)
DE (1) DE69824853T2 (de)
ES (1) ES2224355T3 (de)
HK (1) HK1028190A1 (de)
NO (1) NO327175B1 (de)
NZ (1) NZ337077A (de)
WO (1) WO1998034644A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408323C (en) 2000-05-08 2012-06-12 The University Of British Columbia Drug delivery systems for photodynamic therapy
WO2002064163A2 (en) * 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation
NL1020336C2 (nl) * 2002-04-09 2003-10-13 Photobiochem Leiden N V Toepassing van een verbinding voor de bereiding van een farmaceutisch preparaat voor het behandelen van brandwonden, en een werkwijze voor het behandelen van brandwonden.
WO2006015016A2 (en) 2004-07-30 2006-02-09 Massachusetts Eye And Ear Infirmary Photodynamic therapy and compositions for treating ocular glaucoma
US7479136B2 (en) * 2005-04-14 2009-01-20 Dotson Robert S Ophthalmic phototherapy treatment method
US20080269730A1 (en) * 2005-04-14 2008-10-30 Dotson Robert S Ophthalmic Phototherapy Device and Associated Treatment Method
US20130079759A1 (en) 2005-04-14 2013-03-28 Robert S. Dotson Ophthalmic Phototherapy Device and Associated Treatment Method
US20060235493A1 (en) * 2005-04-14 2006-10-19 Dotson Robert S Ophthalmic phototherapy device and associated treatment method
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
US10918719B2 (en) * 2014-02-28 2021-02-16 Massachusetts Eye And Ear Infirmary Methods for cross-linking corneal collagen with verteporfin for the treatment of disorders of the eye
SG11201701777PA (en) 2014-09-09 2017-04-27 Lumithera Inc Multi-wavelength phototherapy devices, systems, and methods for the non-invasive treatment of damaged or diseased tissue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5283255A (en) 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
ES2110002T3 (es) 1991-06-21 1998-02-01 Baxter Int Procedimiento de inactivacion de agentes patogenos en fluidos corporales.
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
US5707986A (en) 1994-03-14 1998-01-13 Miller; Joan W. Angiographic method using green porphyrins in primate eyes
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye

Also Published As

Publication number Publication date
DE69824853T2 (de) 2006-01-12
CA2279427A1 (en) 1998-08-13
CN1269729A (zh) 2000-10-11
HK1028190A1 (en) 2001-02-09
JP2002509531A (ja) 2002-03-26
WO1998034644A1 (en) 1998-08-13
NO993841L (no) 1999-10-08
ATE270114T1 (de) 2004-07-15
AU5777298A (en) 1998-08-26
NO327175B1 (no) 2009-05-04
CA2279427C (en) 2009-11-24
CZ282299A3 (cs) 2000-02-16
NZ337077A (en) 2001-06-29
CZ295734B6 (cs) 2005-10-12
JP4012575B2 (ja) 2007-11-21
EP0996465B1 (de) 2004-06-30
US6677366B2 (en) 2004-01-13
AU734366B2 (en) 2001-06-14
ES2224355T3 (es) 2005-03-01
EP0996465A1 (de) 2000-05-03
NO993841D0 (no) 1999-08-10
CN1187089C (zh) 2005-02-02
JP2005272464A (ja) 2005-10-06
US20020103180A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
ATE214609T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leberkrankheiten
EP0209689A3 (en) Use of tetrahydrobiopterins in the treatment of infantile autism
ATE433756T1 (de) Gelierte zusammensetzungen
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
MX9803563A (es) Preparacion terapeutica para la administracion transdermica de principios activos.
MX9305146A (es) Conjugado de interferon, procedimiento para su preracion y composicion farmaceutica que lo contienen.
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
UA41316C2 (uk) Трициклічні похідні піролу і фармацевтичний препарат
ATE153853T1 (de) Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
DE69824853D1 (de) Zusammensetzungen und gegenstände zur verminderung der auswirkung von entzündungen
PT902789E (pt) Derivados de androsteno
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
ES2178188T3 (es) Composiciones antitusigenas que contienen teobromina.
FI940696A0 (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
DE69941629D1 (de) Durchsichtige transdermale nicotinabgabevorrichtungen
SE8600496D0 (sv) Pharmaceutical 9,10-dihydro ergot alkaloid containing compositions
WO2000038620A3 (en) A composition useful to treat periodontal disease
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
DK318589A (da) 19-substituerede progesteron-derivater, anvendelige som 19-hydroxylase-inhibitorer
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
ES2062125T3 (es) Una composicion farmaceutica que contiene derivados de hidantoina.
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
ATE102934T1 (de) Fluorierte flavon-essigsaeure.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition